X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TTI-101, an orally delivered, small molecule, direct inhibitor of STAT3, is being developed alone or in combination with nintedanib in phase 2 trial in patients with idiopathic pulmonary fibrosis.
Lead Product(s): TTI-101
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TTI-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2023
Details:
TTI-101, an orally delivered, small molecule, direct inhibitor of STAT3, is being developed in phase 3 trial in patients with locally advanced or metastatic, and unresectable hepatocellular carcinoma (HCC).
Lead Product(s): TTI-101
Therapeutic Area: Oncology Product Name: TTI-101
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
TTI-101 is an orally bioavailable, small-molecule inhibitor of signal transducer and activator of transcription 3, a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis.
Lead Product(s): TTI-101,Palbociclib
Therapeutic Area: Oncology Product Name: TTI-101
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
TTI-101 is an orally delivered, small molecule, direct inhibitor of STAT3. STAT3 is a key regulatory protein which plays a critical role in the pathogenesis of HCC by initiating tumorigenesis as well as promoting an immunosuppressive tumor microenvironment.
Lead Product(s): TTI-101,Pembrolizumab
Therapeutic Area: Oncology Product Name: TTI-101
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Details:
TTI-101 is an orally-delivered, small molecule, direct STAT3 inhibitor. STAT3 has emerged as a central node of fibrosis and has been found to accumulate in the fibrotic lungs of IPF patients.
Lead Product(s): TTI-101
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TTI-101
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
TTI-101 is an orally delivered, small molecule, direct inhibitor of STAT3. STAT3 is a key regulatory protein which plays a critical role in the pathogenesis of HCC by initiating tumorigenesis as well as promoting an immunosuppressive tumor microenvironment.
Lead Product(s): TTI-101
Therapeutic Area: Oncology Product Name: TTI-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2022
Details:
Studies demonstrated that combination of TTI-101 with palbociclib is synergistic in arresting tumor growth in murine models derived from metastatic breast cancer patients who had developed resistance to palbociclib.
Lead Product(s): TTI-101,Palbociclib
Therapeutic Area: Oncology Product Name: TTI-101
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022
Details:
The company’s lead product, TTI-101, is currently being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy.
Lead Product(s): TTI-101
Therapeutic Area: Oncology Product Name: TTI-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Slate Path Capital
Deal Size: $74.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 27, 2021
Details:
Funding to support clinical trials of TTI-101 in hepatocellular carcinoma and gastrointestinal cancer as well as funding from the PREVENT program to support translational work of TTI-101 in HCC prevention.
Lead Product(s): TTI-101
Therapeutic Area: Oncology Product Name: TTI-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Funding July 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
